Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Benoist 2014, PMID 25187433) were retracted in April 2025 (retraction notices PMID 40312092 and PMID 40312093) following a Washington State University investigation that found the lead author altered images across her dissertation and multiple co-authored papers
Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease
Recovery peptides like BPC-157 (which you can calculate using the BPC-157 dosage calculator ) or TB-500 target tissue repair rather than metabolic receptors and operate through non-overlapping mechanisms
Xiong S et al
